Overview

A Study of Xiangjurupining Capsule in the Treatment of Hyperplasia of Breast (Liver Stagnation and Phlegm Coagulation)

Status:
Recruiting

Trial end date:
2022-05-30

Target enrollment:

Participant gender:

Summary

The study is to evaluate the efficacy and safety of two doses of xiangjurupining capsule in Hyperplastic disease of breast patients .

Phase:

Phase 2

Details

Lead Sponsor:

Tasly Pharmaceuticals, Inc.